Dx Profiler: Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?
- Review of the Initial Results from Basket Trials
- Implications of Initial Results in Patients with Metastatic Cancer and Diagnostic Ambiguity
- Improving Diagnostic Certainty: The Role of Molecular Assays in Challenging Cases
- Performance of the CancerTYPE ID Molecular Classifier
The application of molecularly targeted cancer therapies has rapidly expanded in the past 2 decades. The identification of genetic mutations in tumors has led to a growing list of therapies developed to specifically target those alterations. Indeed, molecularly targeted therapies—along with predictive biomarker testing and site-specific chemotherapy—have significantly improved the [ Read More ]